Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22895Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kontostolis, E. | en |
| dc.contributor.author | Stefanidis, K. | en |
| dc.contributor.author | Navrozoglou, I. | en |
| dc.contributor.author | Lolis, D. | en |
| dc.date.accessioned | 2015-11-24T19:28:25Z | - |
| dc.date.available | 2015-11-24T19:28:25Z | - |
| dc.identifier.issn | 0951-3590 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22895 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Cohort Studies | en |
| dc.subject | Danazol/adverse effects/*therapeutic use | en |
| dc.subject | Estrogen Antagonists/adverse effects/*therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Pain/drug therapy/etiology | en |
| dc.subject | Premenstrual Syndrome/*drug therapy | en |
| dc.subject | Prospective Studies | en |
| dc.subject | Reference Values | en |
| dc.subject | Tamoxifen/adverse effects/*therapeutic use | en |
| dc.title | Comparison of tamoxifen with danazol for treatment of cyclical mastalgia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/9476088 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1997 | - |
| heal.abstract | This study evaluates the benefits and side-effects of two drugs (tamoxifen or danazol) used randomly in women with severe cyclical mastalgia. Ninety-three patients with severe cyclical mastalgia of more than 6 months duration were randomly selected for treatment with tamoxifen (32 women), danazol (32 women) or placebo (29 women) for six consecutive cycles. A standard protocol was used, which included pain relief as measured by linear analog, side-effects and cost. Statistical analysis was performed using the non-parametric Mann-Whitney U or Kruskall-Wallis tests and Student's t-test. As measured by linear analog scoring, pain relief was achieved in 23/32 (72%) of those receiving tamoxifen, 21/32 (65%) of those taking danazol (p < or = 0.001) and 11/29 (38%) of those taking placebo. Twelve months after the end of treatment, 17 (53%) women who received tamoxifen were still free of symptoms, as compared with 12 (37%) of the danazol-treated patients (p < 0.001) and none of the placebo-treated patients. These results suggest that tamoxifen is highly efficaceous and cost effective for the management of severe cyclical mastalgia. | en |
| heal.journalName | Gynecol Endocrinol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
